Importantly, our in vivo experiments revealed that in tumors with elevated SAG levels, inhibiting Ces1c markedly impairs melanoma tumor growth, highlighting CES1 as a potential therapeutic target for malignant melanoma. This evidence concerns the gene CES1 and neoplasm.